The deal sets up a multi-year collaboration on hematopoietic stem cell and T-cell editing with the San Raffaele Telethon Institute for Gene Therapy.
The grant from the California Institute of Regenerative Medicine will fund research on two approaches to DMD gene therapy using CRISPR/Cas9.
A bacterial argonaute protein is being touted as a DNA-guided, DNA-targeting genome editor, but some scientists are having trouble reproducing those results.
The researchers also developed a mouse model of the mutation using CRISPR/Cas9 genome engineering to examine its effects.
While reimbursement and regulatory issues may make some cautious, investors are encouraged by the promise of breakthrough outcomes in a variety of applications.
In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.
Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.
Olympic athletes this summer will also undergo gene doping testing, according to Wired.
A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.